ArticleRadiation oncology (London, England)2016
[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.
Article in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.Frontiers in medicine · 2026Pooled it
- Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity.Acta oncologica (Stockholm, Sweden) · 2024Pooled it
- Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic review.Clinical & experimental metastasis · 2022Pooled it
- Radiotherapy of oligometastatic prostate cancer: a systematic review.Radiation oncology (London, England) · 2021Pooled it
- Systematic review of stereotactic body radiotherapy for nodal metastases.Clinical & experimental metastasis · 2021Pooled it
- Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Trial
- Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published Data.Cancers · 2025Review
- Uncovering the armpit of SBRT: An institutional experience with stereotactic radiation of axillary metastases.Clinical and translational radiation oncology · 2024Article
- The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.Prostate cancer and prostatic diseases · 2023Review
- Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.Seminars in radiation oncology · 2023Review
- Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy.Journal of cancer research and clinical oncology · 2023Article
- Stereotactic radiotherapy for oligometastases in the lymph nodes.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Review
- Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.Clinical & experimental metastasis · 2021Article
- [EJNMMI research · 2021Article
- Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer.Seminars in radiation oncology · 2021Review
- Single-Center Experience of Focal Thermo-Ablative Therapy After Pelvic Radiotherapy for In-Field Prostate Cancer Oligo-Recurrence.Frontiers in oncology · 2021Article
- Unusual uptakes onQuantitative imaging in medicine and surgery · 2021Article
- Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.International journal of radiation oncology, biology, physics · 2020Article
- Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study.European journal of nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundA new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [(18)F]Choline ([(18)F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa).
methodsTwenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [(18)F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [(18)F]FMCHPET/CT.
resultsA total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3-40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20-62.14 months). No grade 3 or 4 toxicity was recorded.
conclusionsRepeated salvage [(18)F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.